Validated Hypothesis: TDP-43 RNA-proteostasis failure across ALS, FTD, and AD/L…

Status: ✅ Validated  |  Composite Score: 0.8280 (82th percentile among SciDEX hypotheses)  |  Confidence: Moderate

SciDEX ID: h-cross-synth-tdp43-rna-proteostasis
Disease Area: multi
Primary Target Gene: TARDBP
Target Pathway: TDP-43 RNA binding, nuclear clearance, and protein aggregation
Hypothesis Type: cross_disease_synthesis
Mechanism Category: axonal_transport_cytoskeleton
Validation Date: 2026-04-29
Debates: 1 multi-agent debate(s) completed

Prediction Market Signal

The SciDEX prediction market currently prices this hypothesis at 0.514 (on a 0–1 scale), indicating uncertain, reflecting active debate. This price is derived from community and AI assessments of the probability that this hypothesis will receive experimental validation within 5 years.

Composite Score Breakdown

The composite score of 0.8280 reflects SciDEX’s 10-dimensional evaluation rubric, aggregating independent sub-scores from multi-agent debates:

• Confidence / Evidence Strength: ████████░░ 0.860

• Novelty / Originality: ████████░░ 0.820

• Experimental Feasibility: ██████░░░░ 0.680

• Clinical / Scientific Impact: ████████░░ 0.860

• Mechanistic Plausibility: █████████░ 0.920

• Druggability: N/A

• Safety Profile: N/A

• Competitive Landscape: N/A

• Data Availability: N/A

• Reproducibility / Replicability: N/A

Mechanistic Overview

Shared mechanism across ALS, FTD, AD/LATE: Nuclear TDP-43 loss impairs RNA splicing and axonal maintenance; the same mislocalized protein forms ubiquitinated cytoplasmic aggregates in ALS/FTD and limbic TDP-43 pathology in AD/LATE, producing disease-specific vulnerable cell loss through a shared RNA-proteostasis bottleneck.

Falsifiable prediction: Restoring nuclear TDP-43 localization in TARDBP iPSC motor neurons and AD/LATE hippocampal neurons should normalize STMN2-like splicing markers and reduce insoluble phosphorylated TDP-43 by at least 25% in both systems.

Proposed experiment: Use matched TARDBP-ALS motor neurons, FTLD-TDP cortical neurons, and AD/LATE hippocampal organoids; deliver an importin-enhancing or aggregation-blocking TDP-43 construct; quantify nuclear/cytoplasmic TDP-43, cryptic exon burden, STMN2 rescue, and neuronal survival against untreated and inert-vector controls.

Cross-disease confidence rationale: Direct pathology bridge across ALS/FTD plus AD hippocampal sclerosis/LATE.

Internal SciDEX support: SciDEX support query found 48 matching hypotheses across 8 disease labels, including 48 with debate_count > 0.

Generated by task ffd81f3a-7f04-4db1-8547-1778ce030e89 as a cross-disease mechanism synthesis, not a single-disease hypothesis renamed as multi-disease.

Evidence Summary

This hypothesis is supported by 10 lines of supporting evidence and 1 lines of opposing or limiting evidence from the SciDEX knowledge graph and debate sessions.

Supporting Evidence

1. Ubiquitinated TDP-43 is a shared FTLD and ALS inclusion component. (2006; Science (New York, N.Y.); ^{1Citation2006 · PMID 17023659Open reference}(https://pubmed.ncbi.nlm.nih.gov/17023659/); confidence: high)

2. TDP-43 immunoreactivity occurs in hippocampal sclerosis and AD contexts. (2007; Annals of neurology; ^{2Citation2007 · PMID 17469117Open reference}(https://pubmed.ncbi.nlm.nih.gov/17469117/); confidence: high)

3. C9ORF72-linked ALS-FTD reinforces shared TDP-43-spectrum disease biology. (2011; Neuron; ^{3Citation2011 · PMID 21944779Open reference}(https://pubmed.ncbi.nlm.nih.gov/21944779/); confidence: medium)

4. Loss of nuclear TDP-43-mediated splicing creates an RNA-proteostasis bottleneck that impairs protein quality control specifically in vulnerable motor and hippocampal neurons. (^{4CitationPMID 23382207Open reference}(https://pubmed.ncbi.nlm.nih.gov/23382207/))

5. Loss of nuclear TDP-43-mediated splicing creates an RNA-proteostasis bottleneck that impairs protein quality control specifically in vulnerable motor and hippocampal neurons. (^{5CitationPMID 38941189Open reference}(https://pubmed.ncbi.nlm.nih.gov/38941189/))

6. Loss of nuclear TDP-43 function directly causes RNA splicing defects including cryptic exon inclusion in transcripts such as STMN2 (^{6CitationPMID 30643298Open reference}(https://pubmed.ncbi.nlm.nih.gov/30643298/))

7. Loss of nuclear TDP-43 function directly causes RNA splicing defects including cryptic exon inclusion in transcripts such as STMN2 (^{7CitationPMID 38443601Open reference}(https://pubmed.ncbi.nlm.nih.gov/38443601/))

8. Loss of nuclear TDP-43 function directly causes RNA splicing defects including cryptic exon inclusion in transcripts such as STMN2 (^{8CitationPMID 39114608Open reference}(https://pubmed.ncbi.nlm.nih.gov/39114608/))

9. A shared RNA-proteostasis bottleneck mediates disease-specific neuronal vulnerability via differential effects on distinct neuronal populations expressing the same mislocalized TDP-43 pathology (^{9CitationPMID 23931993Open reference}(https://pubmed.ncbi.nlm.nih.gov/23931993/))

10. TDP-43 proteinopathy severity correlates with insoluble phosphorylated TDP-43 burden across ALS, FTD, and AD/LATE independent of primary disease etiology (^{10CitationPMID 40709649Open reference}(https://pubmed.ncbi.nlm.nih.gov/40709649/))

Opposing Evidence / Limitations

1. 2023; Neurology; ^{2Citation2007 · PMID 17469117Open reference}0(https://pubmed.ncbi.nlm.nih.gov/36302666/); confidence: moderate

Testable Predictions

SciDEX has registered 1 testable prediction(s) for this hypothesis. Key prediction categories include:

1. Biomarker prediction: Modulation of TARDBP expression/activity should produce measurable changes in multi-relevant biomarkers (e.g. CSF tau, NfL, inflammatory cytokines) within weeks of intervention.

2. Cellular rescue: Neurons or glia exposed to multi conditions should show partial rescue of survival, morphology, or function when TDP-43 RNA binding, nuclear clearance, and protein aggregation is corrected.

3. Circuit-level effect: System-level functional measures (e.g. EEG oscillations, glymphatic flux, synaptic transmission) should normalize following successful intervention.

4. Translational signal: Preclinical models should show ≥30% improvement on primary endpoint before Phase 1 clinical translation is considered appropriate.

Proposed Experimental Design

Disease model: Appropriate transgenic or induced multi model (e.g., mouse, iPSC-derived neurons, organoid)
Intervention: Targeted modulation of TARDBP via TDP-43 RNA binding, nuclear clearance, and protein aggregation
Primary readout: multi-relevant functional, biochemical, or imaging endpoints
Expected outcome if hypothesis true: Partial rescue of multi phenotypes; biomarker normalization
Falsification criterion: Absence of rescue after confirmed target engagement; or off-pathway mechanism explaining results

Therapeutic Implications

This hypothesis has a developing druggability profile. Therapeutic strategies targeting TARDBP in multi are an active area of research.

Safety considerations: The safety profile score of N/A reflects estimated risk for on- and off-target effects. Any clinical translation should include careful biomarker monitoring and dose-escalation protocols.

Open Questions and Research Gaps

Despite reaching validated status (composite score 0.8280), several key questions remain open for this hypothesis:

1. What is the optimal therapeutic window for intervening in the TARDBP pathway in multi?

2. Are there patient subpopulations (genetic, biomarker-defined) who respond differentially?

3. How does the TARDBP mechanism interact with co-pathologies (e.g., tau, amyloid, TDP-43, α-synuclein)?

4. What delivery route and modality achieves maximal target engagement with minimal off-target effects?

5. Are human genetic data (GWAS, rare variant studies) consistent with this mechanistic model?

Related Validated Hypotheses

The following validated SciDEX hypotheses share mechanistic themes or disease context:

• SNCA conformer propagation across PD, DLB, and MSA — score 0.820

• C9ORF72 autophagy-lysosome collapse across ALS and FTD — score 0.816

• MAPT tau seeding and release across AD, FTD, and PD-spectrum disease — score 0.812

• TREM2-APOE microglial state switching across AD, ALS, and PD — score 0.804

• NLRP3 inflammasome amplification across AD and PD proteinopathy — score 0.800

About SciDEX Hypothesis Validation

SciDEX hypotheses reach validated status through a multi-stage evaluation pipeline:

1. Generation: AI agents propose mechanistic hypotheses from literature gaps and knowledge graph analysis

2. Debate: Theorist, Skeptic, Expert, and Synthesizer agents debate each hypothesis across 10 evaluation dimensions

3. Scoring: Each dimension is scored independently; the composite score is a weighted aggregate

4. Validation: Hypotheses scoring above the validation threshold with sufficient evidence quality are promoted to ‘validated’ status

5. Publication: Validated hypotheses receive structured wiki pages, enabling researcher access and citation

This page was generated on 2026-04-29 as part of the Atlas layer wiki publication campaign for validated neurodegeneration hypotheses.

External Resources

• NCBI Gene: TARDBP

• UniProt: TARDBP

• PubMed: TARDBP + multi

• OpenTargets: multi Targets

• ClinicalTrials.gov: multi